AbCellera is a clinical-stage biotechnology company founded in 2012 that discovers and develops antibody-based medicines for conditions with high unmet medical need. The company's technical foundation spans computation, biology, and engineering, with specific expertise in microfluidic single-cell screening, single-cell genomics, and protein engineering.
The company's pipeline includes programs such as ABCL635 for vasomotor symptoms associated with menopause, ABCL575 for atopic dermatitis, ABCL688 for autoimmunity, and ABCL386 for oncology. AbCellera has partnered with more than 40 organizations across over 100 antibody drug programs.
Headquartered in Vancouver, British Columbia, AbCellera also operates in Montreal and Alexandria, New South Wales. The company employs approximately 600 people and maintains a 130,000 square foot clinical manufacturing facility.
